FDA Webview
X
about-us-banner

Articles

Home /Articles / FDA Federal Register Notices

Guidance on Human Factor Studies for Combo Products

02/03/2016

Federal Register Notice: FDA is making available a draft guidance for industry and FDA staff entitled Human Factors Studies and Re...

Comments Sought on Combo Product Assignment Procedure

01/28/2016

Federal Register Notice: FDA seeks public comments on the procedure by which an applicant may obtain an assignment or designation ...

Draft Guidance on Lamotrigine BE Recommendations

01/28/2016

Federal Register Notice: FDA is making available a revised draft guidance for industry on lamotrigine extended-release tablets ent...

FDA Releases Product-Specific BE Guidance

01/28/2016

Federal Register Notice: FDA is making available additional draft and revised draft product-specific bioequivalence (BE) recommend...

FDA, Xavier University Plan Device Conference

01/28/2016

Federal Register Notice: FDA’s Cincinnati District and Xavier University will co-sponsor a public conference 5/4-6 entitled ...

Panel to Discuss Leadless Cardiac Pacemakers

12/14/2015

Federal Register Notice: FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet 2/18/16,...

Review Period Set for Sirturo

12/10/2015

Federal Register Notice: FDA has determined the regulatory review period for Janssen Pharmaceutica’s Sirturo is 2,213 days f...

Review Period Set for Eliquis

12/10/2015

Federal Register Notice: FDA has determined the regulatory review period for Bristol-Myers Squibb’s Eliquis is 3,685 days fo...

Review Period Set for Visual Stimulation System

12/10/2015

Federal Register Notice: FDA has determined the regulatory review period for Second Sight Medical Products’ Argus II Visual ...

Review Period Set for Bayer Animal Health’s Veraflox

12/10/2015

Federal Register Notice: FDA has determined the regulatory review period for Bayer Animal Health’s Veraflox is 3,285 days fo...